Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature

Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d’Agostino M-A, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014;67(7):745–53.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.

Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729–40.

Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol. 2007;34(5):1174–7.

Kilic L, Erden A, Bingham CO, Gossec L, Kalyoncu U. The reporting of patient-reported outcomes in studies of patients with rheumatoid arthritis: a systematic review of 250 articles. J Rheumatol. 2016;43:1300–5.

Masri KR, Shaver TS, Shahouri SH, Wang S, Anderson JD, Busch RE, et al. Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as used in clinical practice. J Rheumatol. 2012;39(6):1139–45.

Curtis JR, Shan Y, Harrold L, Zhang J, Greenberg JD, Reed GW. Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. Arthritis Care Res (Hoboken). 2013;65(10):1707–12.

Scott PJ, Huskisson EC. Measurement of functional capacity with visual analogue scales. Rheumatol Rehabil. 1977;16(4):257–9.

Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, et al. Updating the OMERACT filter: implications for patient-reported outcomes. J Rheumatol. 2014;41(5):1011–5.

Hewlett S, Nicklin J, Bode C, Carmona L, Dures E, Engelbrecht M, et al. Translating patient reported outcome measures: methodological issues explored using cognitive interviewing with three rheumatoid arthritis measures in six European languages. Rheumatology (Oxford). 2016;55:1009–16.

French T, Hewlett S, Kirwan J, Sanderson T. Different wording of the Patient Global Visual Analogue Scale (PG-VAS) affects rheumatoid arthritis patients’ scoring and the overall Disease Activity Score (DAS28): a cross-sectional study. Musculoskeletal Care. 2013;11(4):229–37.

Khan NA, Spencer HJ, Abda EA, Alten R, Pohl C, Ancuta C, et al. Patient’s global assessment of disease activity and patient’s assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? Ann Rheum Dis. 2012;71(12):1942–9.

Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, et al. Determinants of discordance in patients’ and physicians’ rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64(2):206–14.

Harrison MJ, Boonen A, Tugwell P, Symmons DPM. Same question, different answers: a comparison of global health assessments using visual analogue scales. Qual Life Res. 2009;18(10):1285–92.

Kalyoncu U, Dougados M, Daurès J-P, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2009;68(2):183–90.

Smedstad LM, Kvien TK, Moum T, Vaglum P. Correlates of patients’ global assessment of arthritis impact. A 2-year study of 216 patients with RA. Scand J Rheumatol. 1997;26(4):259–65.

van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845–50.

Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum. 1980;23(2):146–52.

Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404–13.

Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich K, Filip C, van Eijk-Hustings Y, et al. The EULAR Task Force for standardising minimum data collection in rheumatoid arthritis observational research: results of a hierarchical literature review. Ann Rheum Dis. 2016;75(Suppl 2):166.

Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol. 2005;32(10):2016–24.

Pincus T, Bergman M, Sokka T, Roth J, Swearingen C, Yazici Y. Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol. 2008;35(8):1550–8.

Lati C, Guthrie LC, Ward MM. Comparison of the construct validity and sensitivity to change of the visual analog scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis. J Rheumatol. 2010;37(4):717–22.

Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis. 2009;68(11):1680–5.

Schwartz CE, Andresen EM, Nosek MA, Krahn GL. Response shift theory: important implications for measuring quality of life in people with disability. Arch Phys Med Rehabil. 2007;88(4):529–36.

Bombardier C, Raboud J. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group. Control Clin Trials. 1991;12(4 Suppl):243S–56S.

Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures’ responsiveness to treatment in a randomized controlled trial. Arthritis Rheum. 1995;38(11):1568–80.

Uhlig T, Kvien TK, Pincus T. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis. 2009;68(6):972–5.

Hernández-Cruz B, Cardiel MH. Intra-observer reliability of commonly used outcome measures in rheumatoid arthritis. Clin Exp Rheumatol. 1998;16(4):459–62.

Rohekar G, Pope J. Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. J Rheumatol. 2009;36(10):2178–82.

Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):260–5.

Strand V, Cohen S, Crawford B, Smolen JS, Scott DL. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford). 2004;43(5):640–7.

Pincus T, Richardson B, Strand V, Bergman MJ. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S47–54.

Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Cl. Arthritis Care Res (Hoboken). 2011;63 Suppl 1:S14–36.

Balogh E, Madruga Dias J, Orr C, Mullan R, Harty L, FitzGerald O, et al. Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. Arthritis Res Ther. 2013;15(6):R221.

Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis. 2012;71(10):1702–5.

Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HLM, et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford). 2012;51(6):1076–80.

Aletaha D, Machold KP, Nell VPK, Smolen JS. The perception of rheumatoid arthritis core set measures by rheumatologists. Rheumatology (Oxford). 2006;45(9):1133–9.

Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum. 2011;63(11):3204–15.

Gossec L, Gaujoux-Viala C, Rat A-C, Fautrel B, Saraux A, Guillemin F, et al. OP0003 Are patient global and fatigue predictive of structural outcomes, 3 years later, in patients in remission in early arthritis? Results from the french espoir cohort. Ann Rheum Dis. 2014;71 Suppl 3:53–3.

Gossec L, Kirwan J, Paternotte S, Balanescu A, Boumpas D, de Wit M, et al. FRI0071 Does psychological status drive patient global assessment for rheumatoid arthritis patients who do not have any clinical signs of inflammation? an exploratory analysis of near-remission using the rheumatoid arthritis impact of disease (RAID) score. Ann Rheum Dis. 2014;72 Suppl 3:A393–3.

Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 2012;64(9):2814–23.

Nicolau G, Yogui MM, Vallochi TL, Gianini RJ, Laurindo IMM, Novaes GS. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol. 2004;31(7):1293–6.

Diaz-Correa L, Nieves-Plaza M, Santiago-Casas YC, González-Rivera T, Rios G, Vilá LM. Discordance of patient-physician assessments of general health in a US Hispanic population with rheumatoid arthritis—ACR Meeting 2013 abstracts. http://acrabstracts.org/abstract/discordance-of-patient-physician-assessments-of-general-health-in-a-us-hispanic-population-with-rheumatoid-arthritis/ .

Nawito Z, Rady HM, Maged LA. The impact of fibromyalgia on disease assessment in rheumatoid arthritis patients. Egypt Rheumatol. 2013;35(3):115–9.

Kaneko Y, Kuwana M, Kondo H, Takeuchi T. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. J Rheumatol. 2014;41(6):1061–6.

Furu M, Hashimoto M, Ito H, Fujii T, Terao C, Yamakawa N, et al. Discordance and accordance between patient’s and physician’s assessments in rheumatoid arthritis. Scand J Rheumatol. 2014;43(4):291–5.

Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62(6):857–64.

Hirsh JM, Boyle DJ, Collier DH, Oxenfeld AJ, Caplan L. Health literacy predicts the discrepancy between patient and provider global assessments of rheumatoid arthritis activity at a public urban rheumatology clinic. J Rheumatol. 2010;37(5):961–6.

Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 2005;52(12):3873–9.

Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019.

Pope JE, Khanna D, Norrie D, Ouimet JM. The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol. 2009;36(2):254–9.

Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol. 2001;28(4):892–903.

Ward MM. Clinical measures in rheumatoid arthritis: which are most useful in assessing patients? J Rheumatol. 1994;21(1):17–27.

Desthieux C, Hermet A, Granger B, Fautrel B, Gossec L. Patient-physician discordance in global assessment in rheumatoid arthritis: a systematic literature review with metaanalysis. Arthritis Care Res (Hoboken). 2016. doi: 10.1002/acr.22902 . [Epub ahead of print]

Davis JM, Crowson CS, Bongartz T, Michet CJ, Matteson EL, Gabriel SE. Prevalence and correlates of patient-physician discordance in early rheumatoid arthritis—ACR Meeting 2014 abstracts. http://acrabstracts.org/abstract/prevalence-and-correlates-of-patient-physician-discordance-in-early-rheumatoid-arthritis/ .